细胞焦亡现象在大鼠急性心肌梗死无复流模型中的观察分析研究

doi:10.20223/j.cnki.1000-8535.2025.09.011

广州医药 ›› 2025, Vol. 56 ›› Issue (9): 1238-1244.DOI: 10.20223/j.cnki.1000-8535.2025.09.011

细胞焦亡现象在大鼠急性心肌梗死无复流模型中的观察分析研究

陈泳华^1,2, 武泓光², 李希大², 曾军¹, 杨智¹, 苏伟¹, 王巧玲¹, 张昊天², 董豪坚²

1 华南理工大学附属第二医院（广州市第一人民医院）重症医学科（广东广州 510180）;
2 南方医科大学附属广东省人民医院心内科（广东省医学科学院）（广东广州 510080）

收稿日期:2025-04-23 出版日期:2025-09-20 发布日期:2025-10-31
基金资助:
国家重点研发计划（2016YFC1301202）; 广州市中医药和中西医结合科技项目（20222A010002）

Observation and analysis of pyroptosis in the no-reflow model after acute myocardial infarction in rats

CHEN Yonghua^1,2, WU Hongguang², LI Xida², ZENG Jun¹, YANG Zhi¹, SU Wei¹, WANG Qiaoling¹, ZHANG Haotian², DONG Haojian²

1 Department of Critical Care Medicine, Guangzhou First People’s Hospital, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China;
2 Department of Cardiology, Guangdong Provincial People’s Hospital, （Guangdong Academy of Medical Sciences）, Southern Medical University, Guangzhou 510080, China

Received:2025-04-23 Online:2025-09-20 Published:2025-10-31

摘要/Abstract

摘要： 目的建立大鼠急性心肌梗死缺血再灌注后无复流模型,并初步验证细胞焦亡在其中的发生情况。方法选用20只标准成年雄性Sprague Dawley大鼠（体质量260~320 g）,随机分为对照组（n=5）和手术组（n=15）。对照组仅穿线冠状动脉,未行结扎;手术组结扎左前降支0.5 h后解除,进行再灌注4 h,以建立无复流模型。通过Evens blue和硫磺素S染色,评估心肌的正常供血区、再灌注区及无复流区,并对两组大鼠心肌组织进行病理分析。结果对照组大鼠全部存活,未出现无复流现象,心肌组织中未见细胞焦亡。手术组存活13只,形成明确的正常供血区（n=13）、再灌注区（n=13）和无复流区（n=10）。在无复流区的心肌细胞中均观察到细胞焦亡（n=10）,而正常供血区未见（n=0）,再灌注区部分出现（n=4）,差异具有统计学意义（P<0.05）。结论细胞焦亡现象主要存在于大鼠急性心肌梗死缺血再灌注后无复流区域中,细胞焦亡可能作为一种区域特异性程序性死亡方式,在心肌无复流的发生与发展中发挥重要作用。

关键词: 无复流, 细胞焦亡, 急性心肌梗死

Abstract: Objective To establish a rat model of myocardial no-reflow after acute myocardial infarction with ischemia-reperfusion injury and to preliminarily explore the occurrence of pyroptosis in the affected myocardium. Methods Twenty adult male Sprague-Dawley rats（260-320 g）were randomly divided into a control group（n=5）and a surgical group（n=15）. In the control group,the coronary artery was encircled with suture but not ligated. In the surgical group,the left anterior descending artery was ligated for 30 minutes,followed by 4 hours of reperfusion to induce the no-reflow model. Evans blue and thioflavin S staining were used to evaluate the normal perfusion area,reperfusion area,and no-reflow area of the myocardium. Histopathological analysis was conducted on myocardial tissues from both groups. Results All rats in the control group survived without evidence of no-reflow or pyroptosis in myocardial tissue. In the surgical group,13 rats survived and showed distinct regions of normal perfusion,13 with reperfusion,and 10 with no-reflow. Pyroptosis was observed in all no-reflow areas（n=10）,absent in the normal perfusion zones（n=0）,and partially present in the reperfusion zones（n=4）. The differences were statistically significant（P<0. 05）. Conclusions Pyroptosis predominantly occurs in the no-reflow zones following acute myocardial infarction and ischemia-reperfusion injury in rats. As a region-specific form of programmed cell death,pyroptosis may play an important role in the development of myocardial no-reflow.

Key words: no-reflow, pyroptosis, acute myocardial infarction

陈泳华, 武泓光, 李希大, 曾军, 杨智, 苏伟, 王巧玲, 张昊天, 董豪坚. 细胞焦亡现象在大鼠急性心肌梗死无复流模型中的观察分析研究[J]. 广州医药, 2025, 56(9): 1238-1244.

CHEN Yonghua, WU Hongguang, LI Xida, ZENG Jun, YANG Zhi, SU Wei, WANG Qiaoling, ZHANG Haotian, DONG Haojian. Observation and analysis of pyroptosis in the no-reflow model after acute myocardial infarction in rats[J]. Guangzhou Medical Journal, 2025, 56(9): 1238-1244.

参考文献

[1] KONIJNENBERG L S F,DAMMAN P,DUNCKER D J,et al.Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction[J].Cardiovasc Res,2020,116(4):787-805.
[2] DAWSON L P,RASHID M,DINH D T,et al.No-reflow prediction in acute coronary syndrome during percutaneous coronary intervention:The NORPACS risk score[J].Circ Cardiovasc Interv,2024,17(4):e013738
[3] HEUSCH G.Coronary microvascular obstruction:The new frontier in cardioprotection[J].Basic Res Cardiol,2019,114(6):45.
[4] FAN X,REN J,XU Y,et al.Mechanisms underlying coronary no-reflow phenomenon after percutaneous coronary intervention in acute myocardial infarction[J].J Cell Mol Med,2022,26(7):1877-1890.
[5] YELLON D M,HAUSENLOY D J.Myocardial reperfusion injury[J].N Engl J Med,2017,377(11):1121-1135.
[6] CHEN Q,HE Y,SHI Y,et al.Pyroptosis:A novel therapeutic target for cardiovascular diseases[J].Front Cardiovasc Med,2022(9):917142.
[7] MAN S M,KARKI R,KANNEGANTI T D.Molecular mechanisms and functions of pyroptosis,inflammatory caspases and inflammasomes in infectious diseases[J].Immunol Rev,2017,277(1):61-75.
[8] WANG Y,GAO W,SHI X,et al.Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin[J].Nature,2017,547(7661):99-103.
[9] ZHENG Z,LI G,CHEN J,et al.GSDMD-mediated endothelial pyroptosis underlies microvascular dysfunction in ischemia/reperfusion injury[J].J Mol Cell Cardiol,2020(138):204-216.
[10] LIU Y,LEI X,GAO J,et al.Endothelial cell pyroptosis in diabetic retinopathy[J].J Cell Mol Med,2022,26(3):865-876.
[11] 全楚杰,翟永新,梁国泉,等.不同血运重建策略对急性心肌梗死合并多支血管病变患者的疗效对比[J].广州医药,2018,49(2):80-83.
[12] KUUKASJÄRVI P,NORDHAUSEN K,MALMIVAARA A.Reanalysis of systematic reviews:The case of invasive strategies for acute coronary syndromes[J].Int J Technol Assess Health Care,2006,22(4):484-496.
[13] NDREPEPA G,TIROCH K,FUSARO M,et al.5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction[J].J Am Coll Cardiol,2010,55(21):2383-2389.
[14] Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology(ESC),STEG P G,JAMES S K,et al.ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J].Eur Heart J,2012,33(20):2569-2619.
[15] YILDIZ A,YUKSEL M,OYLUMLU M,et al.The utility of the platelet-lymphocyte ratio for predicting no reflow in patients with ST-segment elevation myocardial infarction[J].Clin Appl Thromb Hemost,2015,21(3):223-228.
[16] HARRISON R W,AGGARWAL A,OU F S,et al.Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction[J].Am J Cardiol,2013,111(2):178-184.
[17] ZHANG Y,CHEN X,GUEYDAN C,et al.Plasma membrane changes during programmed cell deaths[J].Cell Res,2018,28(1):9-21.
[18] JIA C,ZHANG J,CHEN H,et al.Endothelial cell pyroptosis plays an important role in Kawasaki disease via HMGB1/RAGE/cathespin B signaling pathway and NLRP3 inflammasome activation[J].Cell Death Dis,2019,10(10):778.
[19] GUO H,CALLAWAY J B,TING J P.Inflammasomes:mechanism of action,role in disease,and therapeutics[J].Nat Med,2015,21(7):677-687.
[20] JI N,QI Z,WANG Y,et al.Pyroptosis:A new regulating mechanism in cardiovascular disease[J].J Inflamm Res,2021(14):2647-2666.
[21] REFAAT H,TANTAWY A,GAMAL A S,et al.Novel predictors and adverse long-term outcomes of no-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].Indian Heart J,2021,73(1):35-43.
[22] SHI H,GAO Y,DONG Z,et al.GSDMD-mediated cardiomyocyte pyroptosis promotes myocardial I/R injury[J].Circ Res,2021,129(3):383-396.
[23] CAO G,JIANG N,HU Y,et al.Ruscogenin attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway[J].Int J Mol Sci,2016,17(9):1418.
[24] ZHU L,YANG Y M,HUANG Y,et al.Shexiang Tongxin dropping pills protect against ischemic stroke-induced cerebral microvascular dysfunction via suppressing TXNIP/NLRP3 signaling pathway[J].J Ethnopharmacol,2024(322):117567.
[25] KAPPELHOFF S,MARGHERITIS E G,COSENTINO K.New insights into gasdermin D pore formation[J].Biochem Soc Trans,2024,52(2):681-692.
[26] ZHENG X,WAN J,TAN G.The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in diabetic retinopathy[J].Front Immunol,2023(14):1151185.

细胞焦亡现象在大鼠急性心肌梗死无复流模型中的观察分析研究

Observation and analysis of pyroptosis in the no-reflow model after acute myocardial infarction in rats

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

本文评价

[1]	文传辉, 刘阳贵, 李北方, 刘飞, 李勇. 回旋支急性闭塞心电图表现及相关临床表现和病变血管特点[J]. 广州医药, 2024, 55(3): 279-283.
[2]	孙李娜. 基于5A模式对急性心肌梗死PCI术后患者早期心脏康复的应用效果[J]. 广州医药, 2023, 54(8): 106-109.
[3]	王鹏川, 朱成朔, 孟庆红. UCG+心肌损伤标志物水平检测在AMI患者诊断中的应用价值[J]. 广州医药, 2023, 54(2): 105-107.
[4]	吴天源, 罗义, 吕磊, 谭文亮, 孙少喜. CYP2C19基因多态性与急性心肌梗死患者炎症指标、临床预后的相关性[J]. 广州医药, 2022, 53(1): 1-5.
[5]	陈希妍, 张建新, 牛丽丹, 孔令宇, 杨飞云, 石金河. 氯吡格雷联合低分子肝素对老年心肌梗死患者血清血脂及炎性因子的影响[J]. 广州医药, 2021, 52(2): 46-49.
[6]	叶飘, 雷晓明. 入院首次中性粒细胞/淋巴细胞比值与急性心肌梗死患者院内主要不良心血管事件发生的相关性研究[J]. 广州医药, 2018, 49(5): 13-17.
[7]	李晓彬, 刘卫明, 齐建雄. 远程早期干预模式在STEMI患者直接经皮冠状动脉介入中的应用疗效[J]. 广州医药, 2018, 49(4): 94-95.
[8]	全楚杰, 翟永新, 梁国泉, 陈以明, 伍文锋. 不同血运重建策略对急性心肌梗死合并多支血管病变患者的疗效对比[J]. 广州医药, 2018, 49(2): 80-83.
[9]	李展鸽, 韩薇薇, 张峻瑞, 刘小红, 蒋凯, 葛利军. 尼可地尔在急性心肌梗死中的研究进展[J]. 广州医药, 2018, 49(1): 105-109.